Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon

著录项

• 来源
  《International Journal of Hematology》 |2012年第4期|p.521-524|共4页
• 作者

  Zaher K. Otrock; Rami A. Mahfouz; Zahera Fahed; Fadi S. Farhat; Azzam Ziade; Fadi Nasr; Nader Kassem; Miguel R. Abboud;

  展开▼
• 作者单位

  Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

  Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon;

  Saint Louis Hospital, Damascus, Syria;

  Hammoud Hospital University Medical Center, Beirut, Lebanon;

  Rafic Hariri University Hospital, Beirut, Lebanon;

  Hôtel-Dieu de France University Hospital, Beirut, Lebanon;

  Al-Rasoul Al-Aazam Hospital, Beirut, Lebanon;

  Department of Pediatrics, American University of Beirut Medical Center, Beirut, Lebanon;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词